Product
L-PZQ
Aliases
L-PZQ ODT 50 mg/kg, L-PZQ ODT 60 mg/kg
1 clinical trial
1 indication
Indication
SchistosomiasisClinical trial
An Open Label, Phase III Efficacy and Safety Study of L-PZQ ODT in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®)Status: Completed, Estimated PCD: 2021-10-11